Current Hypertension Reports

, Volume 14, Issue 1, pp 38–45

Disorders of Blood Pressure Regulation—Role of Catecholamine Biosynthesis, Release, and Metabolism

Authors

  • Gemma Currie
    • Department of EndocrinologyWestern Infirmary
  • E. Marie Freel
    • Institute of Cardiovascular and Medical SciencesUniversity of Glasgow
  • Colin G. Perry
    • Department of EndocrinologyWestern Infirmary
    • College of Medical, Veterinary and Life SciencesUniversity of Glasgow
Pathogenesis of Hypertension: Genetic and Environmental Factors (DT O’Connor, Section Editor)

DOI: 10.1007/s11906-011-0239-2

Cite this article as:
Currie, G., Freel, E.M., Perry, C.G. et al. Curr Hypertens Rep (2012) 14: 38. doi:10.1007/s11906-011-0239-2

Abstract

Catecholamines (epinephrine and norepinephrine) are synthesised and produced by the adrenal medulla and postganglionic nerve fibres of the sympathetic nervous system. It is known that essential hypertension has a significant neurogenic component, with the rise in blood pressure mediated at least in part by overactivity of the sympathetic nervous system. Moreover, novel therapeutic strategies aimed at reducing sympathetic activity show promise in the treatment of hypertension. This article reviews recent advances within this rapidly changing field, particularly focusing on the role of genetic polymorphisms within key catecholamine biosynthetic enzymes, cofactors, and storage molecules. In addition, mechanisms linking the sympathetic nervous system and other adverse cardiovascular states (obesity, insulin resistance, dyslipidaemia) are discussed, along with speculation as to how recent scientific advances may lead to the emergence of novel antihypertensive treatments.

Keywords

EpinephrineNorepinephrineSympathetic nervous systemHypertensionCatecholaminesChromograninsCatestatinReactivityTRPM4Target organ effects

Copyright information

© Springer Science+Business Media, LLC 2011